Epanova(®) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy.
about
Omega-3 carboxylic acids (Epanova): a review of its use in patients with severe hypertriglyceridemia.Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trialLipid pharmacotherapy for treatment of atherosclerosis.An overview of the new frontiers in the treatment of atherogenic dyslipidemias.Emerging approaches for the treatment of hypertriglyceridemia.Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of an Omega-3-Carboxylic Acid Formulation in Healthy Male Japanese Subjects: A Phase 1 Single-Blind, Randomized, Placebo-Controlled Trial.
P2860
Epanova(®) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Epanova(®) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy.
@en
type
label
Epanova(®) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy.
@en
prefLabel
Epanova(®) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy.
@en
P2093
P2860
P356
P1433
P1476
Epanova(®) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy.
@en
P2093
Kiyoko Uno
Rishi Puri
Stephen J Nicholls
Yu Kataoka
P2860
P304
P356
10.2217/FCA.13.4
P577
2013-03-01T00:00:00Z